Clinical Trial Update: Induction Erlotinib Therapy in Stage III A (N2) Non-Small Cell Lung Cancer (NSCLC) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating induction Erlotinib in stage IIIA (N2) non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Guangdong Provincial People's Hospital | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED